Do You Have to Reach the Maximum GLP-1 Dose?

If you’re on a GLP-1, the titration schedule can read like a ladder with a single obvious destination: the top. It’s a natural assumption (more drug, more results), so people often treat the maximum dose as the finish line and feel like they’ve fallen short if they stop climbing. No, you do not have to reach the maximum dose. For many people the best dose is well below the ceiling. The goal is the lowest effective dose, the one that meets your goal with side effects you can live with.

This is a genuine decision worth understanding, not just reassurance. Below is what the trials show about lower doses, and how to think about the trade-off. To see where each step falls on your own calendar, our GLP-1 titration schedule tool maps the whole ladder.

“Maintenance dose” is a range, not a single number

The key thing the schedules don’t make obvious is that some of these drugs have several legitimate maintenance doses, not one target with a bunch of warm-up steps.

Tirzepatide (Zepbound / Mounjaro) is the clearest example. Its approved maintenance doses are 5 mg, 10 mg, and 15 mg. All three are real, on-label endpoints, with 7.5 mg and 12.5 mg serving as intermediate steps on the way up. That’s why the label describes higher steps as “if needed”: the design assumes many people will stop before the top.

The maximum dose is a ceiling, not a target; the right dose is the lowest one that meets your goal with tolerable side effects.

Semaglutide for weight management (Wegovy) is different: it has a single target maintenance dose of 2.4 mg. But even there, the maximum is a ceiling to aim for, not a mandate; some people settle at a lower dose when higher ones bring more side effects than added benefit.

What lower doses deliver

This is where the numbers matter, because “lower dose” doesn’t mean “barely works.” In the SURMOUNT-1 trial of tirzepatide, average weight reductions were:

Tirzepatide dose	Average weight loss	Reached ≥5% loss
5 mg (lowest maintenance)	16.0%	89%
10 mg	21.4%	96%
15 mg (maximum)	22.5%	96%
Placebo	2.4%	28%

Look at the 5 mg row. The lowest maintenance dose produced 16% average weight loss, a result that would have been considered extraordinary for any weight-loss drug a decade ago. Going all the way to the 15 mg maximum added meaningful loss (22.5%), but the jump from 10 mg to 15 mg was comparatively small. In other words, most of the benefit arrives at the lower and middle doses; the top of the ladder adds a final increment, not a transformation.

For context, semaglutide 2.4 mg (Wegovy) produced 14.9% average weight loss versus 2.4% for placebo at 68 weeks in the STEP 1 trial, again showing that these drugs deliver most of their effect well before anyone is pushing extremes.

The trade-off: more dose, more effect, more side effects

If lower doses work, why climb at all? Because, on average, higher doses do produce more weight loss; the SURMOUNT-1 numbers show that clearly. The reason not to reflexively chase the maximum is the other side of the ledger: side effects are dose-related too. Nausea, vomiting, diarrhea, and constipation all tend to increase as the dose goes up.

So the “right” dose is a personal balance point, not a universal number:

• If you’re progressing toward your goal and tolerating your current dose well, there may be no reason to go higher.
• If your results have stalled and side effects are manageable, a step up may be worth discussing.
• If a higher dose brings more side effects than added benefit, staying put, or even stepping back down, is a legitimate choice.

Who might stay below the max on purpose

Several situations make a sub-maximal dose the sensible target rather than a compromise:

• You’ve hit your goal. Once you’re where you want to be, the conversation often shifts from active loss to maintenance, and the dose that got you there, or a lower one, may be all you need to hold it. We compare these two phases in GLP-1s for maintenance vs. active loss.
• Side effects escalate faster than results. If each increase costs you more in nausea than it returns in progress, the lower dose is the better dose for you.
• You’re responding strongly at a low dose. Some people lose well on 5 mg tirzepatide or a sub-2.4 mg semaglutide dose and have no reason to climb.
• Cost or supply. Lower doses can be less expensive or more available, and if they’re working, that’s a real advantage.

Slow and low is the whole design

This is how the drugs were built. The titration schedule ramps slowly precisely so you can find the dose that works for you along the way, rather than defaulting to the top. That “lowest effective dose” philosophy is the same principle behind starting low in the first place, which we cover in why slow GLP-1 titration wins.

The takeaway

The maximum GLP-1 dose is a ceiling, not a goal. Tirzepatide’s lowest maintenance dose already produced 16% average weight loss in trials, and its three approved maintenance doses (5, 10, and 15 mg) are all valid destinations. Higher doses usually add more weight loss but also more side effects, so the best dose is the lowest one that gets you where you want to go while feeling manageable, not automatically the top of the ladder.

Where you land is an individual decision to make with your prescriber, based on your results, your tolerance, and your goal. This article is educational and not medical advice. To see how the steps stack up and plan where you might hold, use our GLP-1 titration schedule tool.

Sources

• SURMOUNT-1 tirzepatide results (NEJM) — Lilly press release
• STEP 1 semaglutide 2.4 mg trial summary — American College of Cardiology
• Zepbound (tirzepatide) Dosage (HCP) — Lilly